Emmecell, a clinical-stage biotechnology company pioneering magnetic cell delivery technologies for ophthalmic disease, today ...

This agreement reinforces Credence’s role as a trusted partner to the pharmaceutical industry in advancing patient care. This ...

YDES YD Bio (NASDAQ:YDES) is an integrated biotechnology company that combines diagnostics, precision medicine, and regenerative ophthalmology under a single commercial and development strategy. The ...

Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more ...

The approved transition to PRF Technologies Ltd. is intended to reflect the Company’s strategy to build long-term value through diversification, platform scalability, and disciplined execution across ...

Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...

Analysis of 20 years of data highlights differences in reimbursement trends across ophthalmology subspecialties and practice ...

BOSTON, MA, UNITED STATES, January 8, 2026 /EINPresswire.com/ -- EyeCool Therapeutics, a clinical-stage ophthalmic ...

On the largest civilian hospital ship in the world, Australian volunteers provide life-changing healthcare that is ...

Aerospace leader brings decades of aviation expertise and a deep commitment to global eye care ...

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA / ACCESS Newswire / January 12, 2026 / Amphastar Pharmaceuticals, ...

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets - - Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 ...